Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function

• US 9,670,545 B2
• Filed: 06/11/2014
• Issued: 06/06/2017
• Est. Priority Date: 06/11/2013
• Status: Active Grant

• Current Assignee: Medicinal Genomics Corporation (Courtagen Life Sciences, Inc.)
• Original Assignee: Courtagen Life Sciences, Inc.
• Inventors: McKernan, Kevin, Boles, Richard
• Primary Examiner(s): KOSSON, ROSANNE
• Application Number:
  US14/895,557
• Publication Number:
  US 20160186264A1
• Time in Patent Office: 1,091 Days
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological and/or mitochondrial dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a change-of-function mutation in nuclear DNA that encodes TNF receptor-associated protein 1 (TRAP1). Treatment involves the administration of a therapeutically effective amount of an antioxidant.

Claims

1. A method of improving mitochondrial function in an individual at risk of or suffering from a mitochondrial dysfunction or disorder, the method comprising administering to the individual a therapeutically effective amount of an antioxidant, wherein DNA of the individual that encodes a TNF receptor-associated protein 1 (TRAP 1) gene product includes a change-of-function mutation, wherein said change-of-function mutation is a loss-of-function mutation.

2. The method of claim 1, wherein, prior to administration, the individual has been determined to possess the change-of-function mutation.

3. The method of claim 1, further comprising determining that the individual possesses the change-of-function mutation.

4. The method of claim 2, wherein the change-of-function mutation is in the ATPase domain or the C-terminal HSP90-like domain.

5. The method of claim 2, wherein the neurological and/or mitochondrial dysfunction or disorder is selected from the group consisting of functional gastrointestinal disorders, chronic pain disorders, chronic fatigue syndrome, intermittent encephalopathy, dementia and combinations thereof.

6. The method of claim 2, wherein the change-of-function mutation causes a changed ATPase activity of a TRAP 1 gene product, wherein the ATPase activity is reduced or increased.

7. The method of claim 2, wherein the change-of-function mutation is or comprises a mutation in the polypeptide of SEQ ID NO:

1 selected from;

(i) the group consisting of 165Q>

E, 192E>

K, 216E>

*, 253I>

V, and combinations thereof, wherein * is a stop codon;

or

(ii) the group consisting of 266S>

R, 340R>

H, 388R>

Q, 444Y>

N, 445G>

S, 457E>

K, 469R>

H, 535T>

S, 685D>

N, and combinations thereof.

8. The method of claim 2, wherein the change-of-function mutation is heterozygous.

9. The method of claim 2, wherein the change-of-function mutation is homozygous.

10. The method of claim 2, wherein the antioxidant is selected from the group consisting of Vitamin C, Vitamin A, Vitamin E, polyphenols, N-acetyl cysteine, Coenzyme Q10, alpha-tocopherol, alpha-tocotrienol, idebenone, cannabidiol, and pharmaceutically acceptable salts thereof.

11. The method of claim 3, wherein determining that the individual possesses the change-of-function mutation comprises requesting sequencing of at least a portion of nuclear DNA that encodes a TRAP 1 gene product.

12. The method of claim 3, wherein determining that the individual possesses the change-of-function mutation comprises sequencing at least a portion of nuclear DNA that encodes a TRAP 1 gene product.

13. The method of claim 3, wherein determining that the individual possesses the change-of-function mutation comprises requesting genotyping of at least a portion of nuclear DNA that encodes a TRAP 1 gene product.

14. The method of claim 3, wherein determining that the individual possesses the change-of-function mutation comprises genotyping at least a portion of nuclear DNA that encodes a TRAP 1 gene product.

15. The method of claim 1, wherein the individual is at risk of or suffers from a neurological dysfunction or disorder.